Report
Håkon Astrup
EUR 86.07 For Business Accounts Only

Sparebank1 SMN (Buy, TP: NOK157.00) - Wings of steel

Despite a sequential slowdown across certain capital-light business areas, MING reported a seasonally strong Q3 with an ROE of 12.4% and sustained benefits from its well-diversified business mix. On top of the soon-to-be-distributed NOK3.1 DPS from 2020, we forecast a 2021e DPS of NOK7.5. Adjusted for this, MING is trading at a fairly undemanding 2022–2023e P/E of 9.2–10.0x. Given the attractive valuation, solid business momentum and our raised 2022–2023e EPS, we have lifted our target price to NOK157 (145) and reiterate our BUY.
Underlying
SpareBank 1 SMN

SpareBank 1 SMN is an independent, regional finance house. Through the SpareBank 1 Alliance and its own subsidiaries (the Bank), Co. has access to products in the fields of financing, savings and investment, insurance and money transfer services. At its Offices business area, the bank provides advice to retail customers, farm sector customers, pools/associations, one-person businesses and small and medium businesses. The Corporate business area focuses on financial counselling in investment and operations financing, domestic and foreign money transfers, fixed income and currency hedging, investment of surplus liquidity and insurance of individuals and buildings/operating equipment.

Provider
DnB Markets
DnB Markets

DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.

 

Analysts
Håkon Astrup

ResearchPool Subscriptions

Get the most out of your insights

Get in touch